REGENXBIO to Present Phase II Trial Results for Experimental AMD Gene Therapy
REGENXBIO Inc. (NASDAQ:RGNX) has recently revealed that they will be sharing the details of their Phase II trial results for their investigational gene therapy, ABBV-RGX-314, aimed at treating wet age-related macular degeneration (AMD). The company is set to present these findings at the Hawaiian Eye and Retina 2024 Meeting, which is scheduled to take place from January 13-19 in Maui, HI.
ABBV-RGX-314 Shows Promising Results in Treating Wet Age-Related Macular Degeneration
The experimental gene therapy, ABBV-RGX-314, being developed by REGENXBIO in collaboration with AbbVie (NYSE:), has demonstrated promising outcomes in the treatment of wet AMD, as well as diabetic retinopathy and other chronic retinal conditions. By utilizing a one-time suprachoroidal delivery method, the therapy aims to address the root causes of these conditions and provide long-lasting relief for patients.
Collaboration Between REGENXBIO and AbbVie Aims to Tackle Chronic Retinal Conditions
REGENXBIO’s collaboration with AbbVie signifies a joint effort to combat chronic retinal conditions that affect a significant number of individuals worldwide. By combining their expertise and resources, both companies are striving to develop effective therapies that can provide meaningful solutions to patients suffering from conditions like wet AMD and diabetic retinopathy.
AAVIATE Study Results for ABBV-RGX-314 to be Presented at Hawaiian Eye and Retina 2024 Meeting
The eagerly awaited results of the Phase II AAVIATE® study, evaluating the efficacy of ABBV-RGX-314, will be presented by Dr. John D. Pitcher, III, from Eye Associates of New Mexico. This presentation will take place on Tuesday, January 16, 2024, at 2:47 p.m. EST, during the Hawaiian Eye and Retina 2024 Meeting. The findings from this study have the potential to provide valuable insights into the effectiveness of ABBV-RGX-314 as a treatment for wet AMD.
REGENXBIO’s Gene Therapy Platform Holds Potential for Treating Various Retinal Disorders
REGENXBIO, a clinical-stage biotechnology company, is known for its innovative gene therapy platform. With exclusive rights to a portfolio of over 100 novel AAV vectors, the company is at the forefront of developing cutting-edge treatments for various retinal disorders. The potential of this platform extends beyond wet AMD and diabetic retinopathy, offering hope for patients suffering from a wide range of chronic retinal conditions.
This announcement from REGENXBIO about the upcoming presentation of Phase II trial results for their experimental gene therapy, ABBV-RGX-314, at the Hawaiian Eye and Retina 2024 Meeting serves as an exciting development in the field of AMD research. The findings of this study have the potential to pave the way for groundbreaking treatments that can significantly improve the lives of patients with wet AMD and other chronic retinal conditions.
Analyst comment
Positive news. The presentation of Phase II trial results for the experimental gene therapy, ABBV-RGX-314, by REGENXBIO at the Hawaiian Eye and Retina 2024 Meeting is an exciting development. The promising outcomes of the therapy in treating wet AMD and other chronic retinal conditions hold potential for groundbreaking treatments and improve the lives of patients. The market is likely to respond positively, with increased investor interest and potential future partnerships.
